Autres langues VYNE Therapeutics Inc.

Actions

VYNE

US92941V3087

Marché Fermé - Nasdaq Autres places de cotation 22:30:00 08/05/2024			Varia. 5j.	Varia. 1 janv.
2,72 ^USD	-5,88 %		+7,51 %	+16,74 %

06/05	VYNE Therapeutics déclare que la FDA américaine a approuvé sa demande de nouveau médicament de recherche pour un traitement auto-immun potentiel	MT
06/05	Vyne Therapeutics annonce l'approbation par la FDA de sa demande d'IND pour Vyn202, un nouvel inhibiteur de BET sélectif du BD2	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

VYNE Therapeutics Says US FDA Clears its Investigational New Drug Application for Potential Autoimmune Treatment	06/05
VYNE Therapeutics Announces FDA Clearance of IND Application for VYN202, a Novel BD2-Selective BET Inhibitor	06/05
Vyne Therapeutics Announces FDA Clearance of IND Application for Vyn202, A Novel Bd2-Selective Bet Inhibitor	06/05
VYNE Therapeutics Announces Oral Presentations for VYN201 at the 2024 Society for Investigative Dermatology (SID) Annual Meeting	01/05
VYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference	19/03
VYNE Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/02
VYNE Therapeutics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	29/02
Earnings Flash (VYNE) VYNE THERAPEUTICS Posts Q4 Revenue $76,000	29/02
VYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business Update	29/02
VYNE Therapeutics to Present Results of the Phase 1b Trial for VYN201 at the 2024 Global Vitiligo Foundation Annual Scientific Symposium	27/02
VYNE Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference	21/02
VYNE Therapeutics Announces Positive Biomarker Data from Successful Phase 1b Trial of VYN201 for the Treatment of Vitiligo	10/01
VYNE Therapeutics Inc. Announces Positive Biomarker Data from Successful Phase 1B Trial of VYN201 for the Treatment of Vitiligo	10/01
VYNE Therapeutics Inc. Appoints Christine Borowski, Ph.D., to Its Board of Directors	03/01
VYNE Therapeutics Appoints Christine Borowski, Ph.D., to its Board of Directors	03/01
Earnings Flash (VYNE) VYNE THERAPEUTICS Posts Q3 Revenue $114,000	13/11
VYNE Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13/11
VYNE Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update	13/11
VYNE Therapeutics to Host Virtual R&D Day Event on November 9, 2023	07/11
VYNE Therapeutics Announces Closing of Previously Announced Private Placement of $88.2 Million	01/11

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues VYNE Therapeutics Inc.

Actions

VYNE

US92941V3087

Autres langues

Filtres